Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • The Body Shops
    • Priced Out
    • Guns, Race, and Profit
    • Broken Rehab
    • Dead Zone
    • Denied
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email
  • Add Us to Google

Friday, Nov 13 2026 UPDATED 9:36 AM

Full Issue

HHS Earmarks Nearly $25M For Research Into Psychedelics As Mental Health Treatment

The Advanced Research Projects Agency for Health and the National Institute of Mental Health will invest millions for research into ibogaine, ketamine, esketamine, and psilocybin as treatments for mental health disorders, including PTSD, as well as for substance use disorders.

The Washington Post: U.S. To Invest Millions In Psychedelics Research On Ibogaine, Psilocybin, Ketamine

The Department of Health and Human Services will invest millions to research and develop psychedelic drugs as mental health treatments, a growing interest for the Trump administration, officials announced Wednesday. The department’s Advanced Research Projects Agency for Health, which funds high-risk, high-reward research projects, will invest up to $4.9 million in ibogaine, a psychedelic that has been touted for its potential to treat military veterans with traumatic brain injuries. (Wu, 11/12)

More mental health news —

NPR: Kratom And 7-OH Can Feel Like 'A Miracle.' They Can Also Be Addictive

Tyler's opioid addiction began in his early 20s, and when he decided he wanted to quit, he used kratom leaf powders to help ease withdrawal symptoms. Tyler, now 38, told NPR he thinks kratom helped him stop using opioids for a decade. (Carlson, 11/13)

STLPR: Autism Diagnoses Among Women Are Rising. A St. Louis Researcher Seeks To Understand Why

When she looks back on her childhood, Lyla Novakowski can pick out the signs of autism. As a child, “I tiptoe-walked everywhere, and they thought that I wanted to be a ballerina,” she said. “I was actually really clumsy. My mom used to call me stubborn and determined.” (Wicentowski, 11/12)

CNN: For 14 Years, An Autistic Boy Lived In Silence. Here’s What He Learned 

Diagnosed with autism by age 3, Payam spent his entire childhood without the ability to speak. “In my experience, it is taught that autistics are unable to really understand much of anything,” Payam explained. “I wish educators would hear the grief and pain as their lessons slowly convince each vibrant child that they do not exist or belong.” (LaMotte, 11/13)

Stat: Across The U.S., Homegrown Experiments Aim To Save Kids From Their Phones

Some programs train ‘attention activists,’ while others look more like AA for iPad kids. (Cueto, 11/13)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, November 13
  • Thursday, November 12
  • Tuesday, November 10
  • Friday, November 6
  • Thursday, November 5
  • Wednesday, November 4
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF